Prostate cancer
- Localized disease: surveillance, surgery or radiation by risk
- Androgen-deprivation therapy is systemic foundation
- Add androgen-receptor pathway drug for metastatic hormone-sensitive disease
- Docetaxel intensifies selected high-volume/high-risk disease
- Castration-resistant disease adds targeted/radioligand/chemo options
- Germline/somatic testing can identify PARP-directed therapy
Use at a glance
- Localized disease: surveillance, surgery or radiation by risk
Treatment options
- Androgen-deprivation therapy is systemic foundation
Other treatment options
- Add androgen-receptor pathway drug for metastatic hormone-sensitive disease
- Castration-resistant disease adds targeted/radioligand/chemo options
- Germline/somatic testing can identify PARP-directed therapy
Choosing treatment
- Docetaxel intensifies selected high-volume/high-risk disease
Self-check
- What is the systemic prostate-cancer treatment foundation?
Androgen deprivation. - What can identify PARP-directed prostate-cancer therapy?
Germline/somatic testing.
Drugs used for this (7)
All clinical uses · Open Prostate cancer in the interactive console ↗